Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: A case series

Clinical Genitourinary Cancer

Volumn 12, Issue 3, 2014, Pages

  Zustovich, Fable ^a   Ferro, Alessandra ^a   Farina, Patrizia ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Antiangiogenic; Cerebral; Kidney; Target therapy; VEGF

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DEXAMETHASONE; EVEROLIMUS; GADOLINIUM; HEPARIN; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTRAST ENHANCEMENT; DISEASE COURSE; DISORIENTATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GENERAL CONDITION DETERIORATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG EMBOLISM; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY; WOUND HEALING IMPAIRMENT; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SECONDARY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84899919807     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.12.005     Document Type: Article

References (11)

1. F. Audenet, D.R. Yates, and G. Cancel-Tassin et al. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine BJU Int 109 2012 1864 1870
2. S. Vanharanta, W. Shu, and F. Brenet et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer Nat Med 19 2013 50 56
3. M.L. Nickerson, E. Jaeger, and Y. Shi et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors Clin Cancer Res 14 2008 4726 4734
4. B.I. Rini Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions Clin Cancer Res 13 2007 1098 1106
5. FDA Gives Roche's Avastin the Go-Ahead for Metastatic Renal Carcinoma. Available at: http://www.genengnews.com/gen-news-highlights/fda-gives-roche-s- avastin-the-go-ahead-for-metastatic-renal-carcinoma/59562374/. Accessed: August 3, 2009.
6. B. Escudier, A. Pluzanska, and P. Koralewski et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
7. B.I. Rini, S. Halabi, and J.E. Rosenberg et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
8. F. Zustovich, G. Lombardi, and D. Pastorelli et al. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome Anticancer Res 30 2010 5213 5216
9. M.E. Gore, C. Szcylik, and C. Porta et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
10. W.M. Stadler, R.A. Figlin, and D.F. McDermott et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 2010 1272 1280
11. J. Beck, G. Procopio, and E. Bajetta et al. Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded access study: a large open-label study in diverse community settings Ann Oncol 22 2011 1812 1823